Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT05030259
Recruiting Observational

The Research About the ACS After Femoropopliteal Arterial Injuries

NCT05030259 · tracked via the Priya Life Science China tracker
Sponsor
Hebei Medical University Third Hospital
Phase
Observational
Started
2021-09-01
Last updated
2021-09-01

Condition(s) studied

Acute Compartment Syndrome

Investigational drug(s) / intervention(s)

fasciotomy

fasciotomy: To perform fasciotomy

Study summary

Crural Compartment syndrome is a well-known sequela after femoropopliteal arterial injuries in the lower extremity, particularly when there has been a long period of ischemia,need for ligation of a major vein, or when there is severe associated soft tissue.There is conteoversy in the treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * patients with femoropopliteal arterial injuries * patients older than 18 years Exclusion Criteria: * Patients who did not survive to discharge * Patients with primary amputation * patients younger than 18 years

Primary outcome measure(s)

  • the rate of amputation — up to 6 months
  • fasciotomy performed or not — up to 2 weeks

Trial sites (1)

FacilityCityRegionStatus
the Third Hospital of Hebei Medical Univesity Shijiazhuang Hebei Recruiting

More Hebei Medical University Third Hospital trials in China

The Research About Acute Compartment Syndrome Recruiting
Researches About Proximal Humerus Fractures Recruiting
Partial Rotator Cuff Injury Combined With Stiff Shoulder Active, not recruiting

Other trials for the same condition

The Research About Acute Compartment Syndrome Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05030259 on ClinicalTrials.gov ↗ ← All trials in China